Close Menu

NEW YORK (GenomeWeb) – Biotage, a Swedish firm specializing in separation technologies, said today it has signed a strategic collaboration with Shandong Yingsheng Biotechnology (Yingsheng) to develop clinical mass spectrometry applications in China.

Terms of the deal call for Biotage to provide systems and consumables from its analytical chemistry portfolio to be sold by Yingsheng under its own brand and together with Yingsheng's other products.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.